131 related articles for article (PubMed ID: 37918680)
1. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease.
Xu S; Kong L; Li L; Wang C; Gu J; Luo H; Meng Q
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166930. PubMed ID: 37918680
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.
Wang Y; Chen C; Chen J; Sang T; Peng H; Lin X; Zhao Q; Chen S; Eling T; Wang X
Redox Biol; 2022 Jun; 52():102322. PubMed ID: 35504134
[TBL] [Abstract][Full Text] [Related]
3. FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease.
Li L; Kong L; Xu S; Wang C; Gu J; Luo H; Meng Q
Hepatol Int; 2024 Feb; 18(1):188-205. PubMed ID: 38183609
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
5. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
6. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
7. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
[TBL] [Abstract][Full Text] [Related]
8. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor).
Zhang L; Chen J; Yang X; Shen C; Huang J; Zhang D; Liu N; Liu C; Zhong Y; Chen Y; Tang K; Guo J; Cui T; Duan S; Li J; Huang S; Pan H; Zhang H; Tang X; Chang Y; Gao Y
Signal Transduct Target Ther; 2024 Jan; 9(1):20. PubMed ID: 38263084
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
11. Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress.
Zilu S; Qian H; Haibin W; Chenxu G; Deshuai L; Qiang L; Linfeng H; Jun T; Minxuan X
Aging (Albany NY); 2019 Dec; 11(24):12177-12201. PubMed ID: 31841118
[TBL] [Abstract][Full Text] [Related]
12. Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance.
Qiu Y; Sui X; Zhan Y; Xu C; Li X; Ning Y; Zhi X; Yin L
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):978-990. PubMed ID: 28153708
[TBL] [Abstract][Full Text] [Related]
13. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
[TBL] [Abstract][Full Text] [Related]
14. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
15. RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome.
Xiang R; Liu Y; Fan L; Jiang B; Wang F
Lab Invest; 2022 Oct; 102(10):1088-1100. PubMed ID: 35690649
[TBL] [Abstract][Full Text] [Related]
16. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
17. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
[TBL] [Abstract][Full Text] [Related]
20. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
